1. Introduction {#sec1}
===============

IFI16 belongs to the IFN-inducible PYHIN-200 gene family \[[@bib1], [@bib2]\] encoding evolutionary related proteins that share a 200-amino acid signature motif (hematopoietic interferon-inducible nuclear, HIN). IFI16 displays two HIN domains separated by a spacer region the length of which is the result of an alternative mRNA splicing leading to the production of three IFI16 isoforms (A, the predominant isoform; B and C; **3**) detectable in several cell types \[[@bib1]\]. IFI16 protein localizes both in nucleus and cytoplasm and it is able to either homodimerize or heterodimerize with different partners including BRCA1, TP53, ASC, RB and STING \[[@bib3], [@bib4], [@bib5], [@bib6], [@bib7], [@bib8]\]. It is noteworthy that IFI16 binds dsDNA sugar phosphate backbone through its positive charged residues in the HIN domain \[[@bib9], [@bib10]\]. Several reports indicated that IFI16 can be considered a DNA sensor involved both in the innate immune response, in particular against viral infections, including HSV-1, HCMV and HIV-1 \[[@bib11], [@bib12], [@bib13], [@bib14], [@bib15], [@bib16], [@bib17]\] and in the activation of the interferon gene pathway. Indeed, IFI16 is required for the cGAMP-induced activation of STING, promoting its phosphorylation and translocation \[[@bib18]\]. IFI16 and cGAS are involved in the activation of the innate immune response to infections by DNA viruses \[[@bib6], [@bib16]\]. The biological role of IFI16 in the cellular biology has been demonstrated by several studies showing that IFI16 regulates proliferation, differentiation, apoptosis/pyroptosis, senescence and inflammation \[[@bib19], [@bib20], [@bib21], [@bib22], [@bib23], [@bib24], [@bib25], [@bib26]\]. More specifically, IFI16 has been shown to down-regulate cell proliferation and to elicit apoptosis in several cell types \[[@bib21], [@bib23], [@bib26]\]. Consistently, IFI16 negatively regulates the cell cycle through binding and functional modulation of several molecules involved in the cell cycle regulation such as TP53, RB, and p21 \[[@bib21], [@bib25], [@bib26]\]. The relationship between IFI16 and differentiation was pointed out during the differentiation of CD34 + hematopoietic stem cells to lymphoid and monocytic lineages \[[@bib1], [@bib27]\]. Furthermore, recent studies have shown that IFI16 expression is modulated in B-cell differentiation \[[@bib28]\]. In particular, IFI16 expression is related to B-cell differentiation stages and it is significantly downregulated during both the transition from naive B-cell subsets to proliferating GC cells and the differentiation of GC-cells to plasma cells, whereas IFI16 expression increases during the shift from GC cells to memory cells \[[@bib28]\]. IFI16 expression is believed to have an intriguing relationship with key transcription factors, including BCL6, NF-κB, STAT3, and STAT5, involved in central processes of the B-cell biology \[[@bib28], [@bib29]\]. Interestingly, gene expression profiling analysis showed that IFI16 expression was inversely related to the expression of the transcription factor BCL6, a master regulator of GC constitution \[[@bib28], [@bib29]\]. IFI16 was also studied as prognostic biomarkers in chronic lymphocytic leukemia (CLL) patients. Interestingly, reduced IFI16 expression was linked to a worse clinical outcome when ZAP70 and CD38 molecules were expressed. Probably, the lack of IFI16, associated with an abridged antiproliferative effect, might be particularly severe in cells constitutively receiving an activation/proliferation signaling. Therefore, the balance between IFI16 expression and activation signaling (mediated by ZAP70/CD38) may be a more reliable prognostic parameter \[[@bib30]\].

In this study, we aimed to assess the expression of IFI16 at gene and protein levels in a large series of B-cell derived non-Hodgkin lymphomas (NHLs), aiming to assess IFI16 expression as a possible prognostic marker in these NHLs.

2. Materials and methods {#sec2}
========================

2.1. Case series {#sec2.1}
----------------

We studied the expression of *IFI16* gene in a discovery cohort of 198 cases for which gene expression profiles (GEPs) were previously generated (GSE12195) \[[@bib31]\]. This data is available on GEO Profiles database (Gene Expression Omnibus of the National Center for Biotechnology Information-NCBI) which stores gene expression profiles derived from curated GEO DataSets. Specifically, we analyzed 46 Burkitt lymphoma (BL), 46 diffuse large B-cell lymphoma (DLBCL), 40 follicular lymphoma (FL), 24 marginal zone lymphoma (MZL), and 22 mantle cell lymphoma (MCL) cases. Furthermore, 20 samples representative of normal B-cell subsets (10 germinal center, GC, 5 naïve, and 5 memory) were also analyzed. In addition, we studied a validation cohort of cases including 86 MCL cases for which GEP were available at the NCBI GEO database (Accession Numbers: [GSE21452](ncbi-geo:GSE21452){#intref0010} and [GSE16455](ncbi-geo:GSE16455){#intref0015}) as well as 106 cases for which formalin fixed paraffin embedded (FFPE) tissue blocks were retrieved at the Hematopathology Unit of S. Orsola-Malpighi Hospital, Bologna University, Bologna, Italy, and used for histopatological examination. The latter cases included 11 BL, 26 DLBCL, 24 FL, 13 MZL, and 32 MCL. All diagnoses were made according to the World Health Organization (WHO) classification.

2.2. Immunohistochemistry on tissue microarrays {#sec2.2}
-----------------------------------------------

A Giemsa-stained slide was prepared from each paraffin block containing representative tumor regions marked on every slide. Tissue cylinders with a diameter of 1.0 mm were punched from the marked areas on each block and placed in a recipient paraffin block using a precision instrument as previously described \[[@bib28], [@bib30]\]. Punches were performed on areas mainly represented by neoplastic cells based on morphological and immunophenotypic evaluation. Tissue microarrays (TMAs) were then prepared for immunohistochemistry.

We studied IFI16 expression by immunohistochemistry (IHC) on TMAs including 32 cases (in duplicate cores). From each recipient block, 1.5 μm-thick sections were cut and tested with anti-IFI16 mouse monoclonal antibody (Sigma, Milan, Italy, dilution 1:100). Briefly, paraffin-embedded sections were dewaxed and submitted to antigen retrieval by heating in Dako PTLink (DakoCytomation, Glostrup, Denmark; code PT100/PT101) in an EnVision Flex Target Retrieval Solution High pH (DakoCytomation; code K8004) at 92 °C for 5 min. Sections were incubated at room temperature with fetal calf serum (10 min) and then with the specific primary antibody (for 30 min). Each evaluation was performed by at least two expert hematopathologists blinded to the study. Scores were compared and consensus agreement was reached at the microscope in all cases.

Immunohistochemistry staining was scored based on the percentage of positive neoplastic cells (visual count performed by two hematopathologists) as follows: 0 = no positive cells; 1 = 1--20%; 2 = 21--40%; 3 = 41--60%; 4 = 61--80%; and 5 = 81--100%. A Semi-quantitative scoring system was used to assess staining intensity and graded as "strong", "weak", and "absent" \[[@bib32]\].

Micrographs were obtained using an Olympus BX61 microscope equipped with an Olympus DP-70 digital camera. Image acquisition, evaluation and color balance were performed using by CellˆF software \[[@bib28], [@bib30]\].

2.3. Gene expression analyses {#sec2.3}
-----------------------------

Gene expression analysis was carried out as previously reported \[[@bib31], [@bib33], [@bib34], [@bib35], [@bib36], [@bib37], [@bib38]\]. Analysis of GEP data in terms of supervised and unsupervised analysis was achieved using GeneSpring GX 12 (Agilent Technologies, Santa Clara, CA, USA). All data were obtained using Affymetrix HG-U133 2.0 plus microarrays (Affymetrix, Inc. <http://www.affymetrix.com/support/index.affx>). Briefly, the expression value of each selected gene was normalized to have a zero mean value and unit standard deviation. The distance between two individual samples was determined by Pearson correlation using the normalized expression values. Unsupervised clustering was generated using a hierarchical algorithm based on the average-linkage method. To perform the supervised gene expression analysis, differentially expressed genes between different groups were identified using a two-tails Student t-test and adjusted Benjamini-Hochberg correction for false discovery rate, applying the following filtering criteria: p-value ≤0.05, and fold change ≥2.

Gene Set Enrichment Analysis (GSEA) was performed to better understand the potential biological significance of the identified molecular signatures. Briefly, GSEA (also known as *functional enrichment analysis*) is a method to identify classes of genes that are over-represented in a large set of genes (molecular or gene signature) and may have a functional association with disease phenotypes \[[@bib39]\]. GSEA of the interested gene sets was performed in terms of Gene Ontology (GO) Biological Processes, Curated Gene Sets and Hallmark Genes using GSEA MsigDB ([www.broadinstitute.org/gsea/msigdb](http://www.broadinstitute.org/gsea/msigdb){#intref0025}) web-based analysis tool \[[@bib39]\], setting the options to the default (displaying top 10 gene sets with FDR q-value below 0.05).

When we focused our analysis on *IFI16* expression, we identified *IFI16* expression using three different probe sets (206332_s\_at; 208966_x\_at; and 208965_s\_at) in the HG-U133 2.0 plus microarray. The median value from the three probes was used for the analysis.

2.4. Statistical analysis {#sec2.4}
-------------------------

Statistical analyses were performed using IBM SPSS Statistics 20.0 and Prism (GraphPad softwares, USA). ANOVA and unpaired T-tests were employed. When a sample size was less than 10 cases in at least 1 group, a non-parametric (Mann-Whitney) test was used to analyze the GEP data to compare *IFI16* expression in different subgroups. Survival analyses were performed by Kaplan-Meier method. Two-sided tests were used in all calculations. The limit of significance for all analyses was defined as p ≤ 0.05.

3. Results and discussion {#sec3}
=========================

3.1. IFI16 gene expression is reduced in mantle cell lymphoma {#sec3.1}
-------------------------------------------------------------

We studied *IFI16* gene expression in the cohort of lymphoma cases, including 46 BL, 46 DLBCL, 40 FL, 24 MZL, and 22 MCL cases ([Fig. 1](#fig1){ref-type="fig"}A). Particularly, we compared gene expression between each tumor type and the corresponding cellular counterpart (i.e. GC cells for BL, FL, and DLBCL and Naïve and/or Memory B-cells for MCL and MZL). Only MCL showed a significant deregulation when compared to the non-neoplastic components (0.123 vs. 0.525; standard error 0.127 vs. 0.059, p = 0.047; [Fig. 1](#fig1){ref-type="fig"}B--F, [Table 1](#tbl1){ref-type="table"}). It should be noted that MCL were compared to both naïve and memory B-cell compartments that represent the postulated counterparts of unmutated and mutated MCL cases, respectively. Since our cases were not distinct based on the immunoglobulin mutational status, naïve/memory subsets have comparable levels of *IFI16* \[[@bib28]\], and *IFI16* is not differentially expressed in mutated vs. unmutated MCL cases \[[@bib40]\], we were confident that this approach could be considered reliable.Fig. 1**IFI16 gene expression in lymphoma subtypes.** Five NHL tumors were compared with their normal counterparts in terms of IFI16 expression, among which only MCL showed altered expression of IFI16.Fig. 1Table 1Descriptive statistics for *IFI16* gene expression in lymphoma subtypes.Table 1CountMeanStd. DevStd. Err.Burkitt lymphoma46-0.1460.6170.091Diffuse large B-cell lymphoma/NOS46-0.190.4480.066Follicular lymphoma400.1040.3060.048Mantle cell lymphoma (training set)220.1230.5950.127Mantle cell lymphoma (validation set)64-0.3750.7660.096Marginal zone lymphoma240.4720.4560.093Germinal center B-cells100.1020.2510.079Memory B-cells50.4980.2420.108Naïve B-cells50.5440.0740.033

A trend toward a reduced expression was also observed in DLBCL; however, the difference was not significant (p = 0.07). Of note, DLBCL were compared to GC only, GEP from plasmablasts, the postulated counterpart of ABC-type DLBCL not being available. Nonetheless, this choice did not seem to affect the analysis since ABC and GCB-type DLBCL did not show differential *IFI16* gene expression \[[@bib41]\].

Thereafter, we studied *IFI16* expression in a validation cohort of cases. When *IFI16* gene expression levels were studied in 64 MCL vs. naïve (N = 5) and memory (N = 5) B-cell samples, an even more evident difference was observed (-0.375 vs. 0.498 vs. 0.544, ANOVA, p-value = 0.002; [Fig. 2](#fig2){ref-type="fig"}A). In fact, again, *IFI16* expression levels were higher than in memory (p = 0.01) and naïve (p = 0.009) B-cell subtypes.Fig. 2**IFI16 expression in validation cohorts**. **A)** IFI16 gene expression in MCL. **B)** IFI16 protein expression at immunohistochemistry: mantle cell lymphoma a) negative and b) weak positive for IFI16 expression; c) follicular lymphoma, d) marginal zone lymphoma, e) diffuse large B-cell lymphoma and f) Burkitt lymphoma showing strong expression for IFI16.Fig. 2

To improve the strength of these data, we also studied IFI16 protein expression by immunohistochemistry in a series consisting of 11 BL, 26 DLBCL, 24 FL, 13 MZL, and 32 MCL. We found a variable degree of expression with positive cases ranging from 31% in MZL to 73% in BL. Concerning MCL, 19/32 cases were positive (59%). Noteworthy, the intensity of the staining was strong in all positive cases with the exception of all MCL and a few FL, in which the staining was weak ([Fig. 2](#fig2){ref-type="fig"}B; [Table 2](#tbl2){ref-type="table"}). A similar pattern has also been observed in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), the first lymphoid neoplasm in which a weak IFI16 expression was documented \[[@bib30]\]. Overall, these data indicate that MCL significantly down-regulates IFI16, even in cases that do not completely abolish its expression.Table 2Immunohistochemical evaluation of IFI16 protein expression.Table 2Lymphoma typeNumber of casesPositive cases (\>20% cells) (%)Staining intensity gradeBurkitt lymphoma118 (72.7)StrongDiffuse large B-cell lymphoma2615 (57.7)StrongFollicular lymphoma248 (33.3)Strong/Weak[∗](#tbl2fnlowast){ref-type="table-fn"}Mantle cell lymphoma3219 (59.4)WeakMarginal zone lymphoma134 (30.8)Strong[^1]

3.2. IFI16 gene down-regulation is associated with increased proliferation and altered metabolism in MCL {#sec3.2}
--------------------------------------------------------------------------------------------------------

We sought to assess whether the expression of IFI16 was associated with the expression of other genes and specific cellular functions. To do so, we studied the transcriptome of B-NHL and normal B-cell subsets, looking for genes with expression levels correlated to those of *IFI16*. We found 93 genes whose expression was significantly related to that of *IFI16* (Pearson correlation \>0.5; [Fig. 3](#fig3){ref-type="fig"}A; [Table 3](#tbl3){ref-type="table"}). Interestingly, at GSEA, they turned out to be significantly involved in interferon response and allograft rejection (as expected based on IFI16 known functions), as well as in other biological processes ([Table 4](#tbl4){ref-type="table"}). Of interest, these findings were, at least in part, validated by the evidence that several of the identified molecules are indeed expressed in MCL, showing sometimes a reduced expression mirroring that of IFI16, including *CD22, BCL11A, FGD2, GPR18, PTPRC, HHEX, PPP1CB*, and *CTSS* \[[@bib42], [@bib43], [@bib44], [@bib45], [@bib46], [@bib47]\].Fig. 3**Association of IFI16 expression with other genes and specific cellular functions.** In A, Hierarchical clustering of MCL and normal B cells (Naive and memory) based on the expression of genes the expression of which is significantly related to that of IFI16 (Pearson correlation \>0.5) is depicted. In Panel B--E, GSEA indicative of metabolic reprogramming in cases with reduced IFI16 expression is presented.Fig. 3Table 3Genes whose expression is significantly related to that of *IFI16* (Pearson correlation \>0.5).Table 3Gene SymbolEntrez GenePearson correlationValidated expression in MCLACTR2100970,669208933ANP32E816110,627841533ARF63820,641927687BANK1550240,67225964BAZ1A111770,630230747BBIP1924820,605706487BCL11A533350,569828467Liu H et al.,2006BCLAF197740,68433418BLOC1S22829910,6491966CD229330,618896733Jovanovic D et al., 2014CDC429980,576680253CEP35098570,617435543CNOT6L2461750,58337405COLCA13999480,616912253CTSS15200,638810313Magunacelaya NM et al.,2004DAPP1270710,635009267DDI2843010,571980767DEGS185600,574676047DICER1234050,592437383DNAJA2102940,648920167EIF3M104800,560212283EIF4G386720,573264233ERBB2IP559140,70120698FGD22214720,607602133Norihiko Kawamata et al., 2005FGD22214720,586247077Norihiko Kawamata et al., 2005GNAI327730,595270897GPR1828410,542490437Henson SE, 2011 and Zhu et al., 2001GVINP13877510,6061212HHEX30870,61690237Nagel S et al., 2018HHEX30870,559629767Nagel S et al., 2018HNRNPU31920,679190433IAH12851480,682675547IFNGR134590,610652857IL10RB35880,61914352KIAA0922232400,610119713KIAA1551551960,620209807KRAS38450,601086023LNPEP40120,633301233MGAT242470,564773553MOB1A552330,565978067NCOA382020,66112306NCOA382020,631385923NIFK843650,628177233NIPBL258360,682132577NUDT4///NUDT4P1///NUDT4P211163///170688///4406720,55685546OPHN149830,576196457P2RY10273340,647883497P2RY10273340,606733317PDIA6101300,549549553PGGT1B52290,6341306PPP1CB55000,618264833Velusamy et al.,2013PRKD3236830,562186867PRPS256340,680414633PRRC2C232150,66378871PRRC2C232150,6341602PRRC2C232150,625491777PTP4A280730,60902381PTPRC57880,644289767Carulli G et al., 2008RAPGEF6517350,578388253RASEF1581580,60727635RHOQ234330,699054647RHOQ234330,630388733RHOQ234330,573807233RIOK387800,603100097RPL3861690,553390113SAMD9548090,54420831SCAF1191690,577746523SEC22B95540,699726023SLC25A1680340,6782821SNX266430,610563997SNX5271310,66154758SP11034310,61964704SP11034310,608826357SRSF10107720,651625337ST8SIA479030,587273833STK467890,63018144SUMO43870820,64389485TMED82835780,660115983TOR1AIP1260920,617741593TRAK2660080,628364817TRIM38104750,6677971TRIM38104750,635720103UBXN4231900,6740565UBXN7260430,5930396WSB1261180,633321007WTAP95890,676307537YWHAZ75340,61512527ZC3H7B232640,53514501ZNF106643970,612370733ZNF20777560,586681463ZNF430802640,631612967ZNF652228340,61678393ZNF665797880,6342984Table 4Gene set enrichment analysis of genes related to *IFI16*.Table 4Gene set categoryGene Set Name\# Genes in Gene Set (K)\# Genes in Overlap (k)k/Kp-valueFDR q-value***Hallmark***ALLOGRAFT REJECTION20060,031,25E-063,12E-05INTERFERON GAMMA RESPONSE20060,031,25E-063,12E-05MITOTIC SPINDLE20040,023,86E-046,43E-03PROTEIN SECRETION9630,03126,00E-047,50E-03***Gene Ontology Biological Process***CELLULAR MACROMOLECULE LOCALIZATION1234150,01222,25E-091,33E-05PROTEIN LOCALIZATION1805170,00947,54E-092,23E-05ESTABLISHMENT OF LOCALIZATION IN CELL1676160,00951,85E-083,65E-05CELL SUBSTRATE JUNCTION39890,02262,70E-083,99E-05CYTOSKELETON ORGANIZATION838110,01311,78E-072,11E-04CELL PROJECTION ORGANIZATION902110,01223,68E-073,63E-04RIBONUCLEOTIDE BINDING1860150,00814,78E-074,04E-04ESTABLISHMENT OF PROTEIN LOCALIZATION1423130,00917,75E-075,63E-04EARLY ENDOSOME30170,02338,56E-075,63E-04POSTTRANSCRIPTIONAL REGULATION OF GENE EXPRESSION44880,01799,90E-075,86E-04

We then compared the cases with the highest (25^th^ percentile) or lowest (25^th^ percentile) *IFI16* gene expression with supervised analysis. We found 79 genes differentially expressed in the two groups ([Table 5](#tbl5){ref-type="table"}); by GSEA they turned out to be significantly involved in cell cycle, cell death and proliferation as well as in other programs ([Table 6](#tbl6){ref-type="table"}). Furthermore, GSEA indicated that the two groups significantly differed as far as certain biological processes related to metabolism were concerned. Particularly, both lipid and glucose metabolism appeared affected ([Fig. 3](#fig3){ref-type="fig"}B--E; [Table 6](#tbl6){ref-type="table"}). Overall, these data indicated that IFI16 deregulation was associated with relevant changes in cell biology.Table 5Gene differentially expressed in cases with higher (75° percentile) vs. lower (25° percentile) *IFI16* gene expression (T-test, p \< 0.05; fold change \>2).Table 5Probe Set IDGene SymbolCorrected pvalueFC (absolute)Regulation in Low229128_s\_at*ANP32E*0,0023723312,6861453Down209642_at*BUB1*0,0122779762,1282046Down231862_at*CBX5*0,0016548862,0196693Down208711_s\_at*CCND1*0,0045133832,067266Down205789_at*CD1D*0,0041464862,0740635Down224428_s\_at*CDCA7*0,0037713092,0563602Down219375_at*CEPT1*1,66E-042,099846Down213060_s\_at*CHI3L2*0,001310522,8916368Down230128_at*CKAP2*0,0156285823,0252607Down203641_s\_at*COBLL1*0,0073595292,1361105Down203642_s\_at*COBLL1*0,0056295722,5396304Down1562836_at*DDX6*0,025110442,0845397Down212503_s\_at*DIP2C*9,26E-042,212788Down222850_s\_at*DNAJB14*0,0056295722,0553403Down219990_at*E2F8*0,0172180442,1936398Down1555996_s\_at*EIF4A2*0,0281803482,023231Down206102_at*GINS1*0,0017412332,1084065Down221922_at*GPSM2*0,0025760292,0255637Down220085_at*HELLS*0,0037095422,3137715Down200679_x\_at*HMGB1*4,27E-042,002743Down230621_at*IAH1*1,53E-042,028879Down206332_s\_at*IFI16*2,07E-102,352239Down208965_s\_at*IFI16*8,91E-042,1735976Down208966_x\_at*IFI16*3,93E-102,4121406Down203819_s\_at*IGF2BP3*0,0086825124,002813Down203820_s\_at*IGF2BP3*0,0101481564,122018Down223176_at*KCTD20*0,00130642,0591123Down227152_at*KIAA1551*0,007075862,0117857Down210313_at*LILRA4*0,0221683442,321087Down235060_at*LOC100190986*0,0017983732,1002595Down235167_at*LOC100190986*0,0090552082,0777555Down229026_at*LOC105379173*0,0201822072,4816926Down230793_at*LRRC16A*0,0026844682,303797Down201151_s\_at*MBNL1*0,0201088122,033717Down222036_s\_at*MCM4*4,09E-042,1149127Down226880_at*NUCKS1*1,65E-042,667727Down223381_at*NUF2*0,0033634322,2747343Down219148_at*PBK*0,0142579692,133363Down201202_at*PCNA*2,63E-042,0165021Down212094_at*PEG10*0,0211578072,0085702Down204285_s\_at*PMAIP1*0,0025593092,0691586Down230352_at*PRPS2*6,56E-052,2383318Down228273_at*PRR11*0,0119470472,3246174Down229147_at*RASSF6*0,0092680343,8838599Down233463_at*RASSF6*0,0032191892,6172767Down235638_at*RASSF6*0,0070680382,7792645Down228455_at*RBM15*0,0024736822,485874Down212027_at*RBM25*0,0056295722,0230834Down228996_at*RC3H1*8,88E-042,6803448Down214257_s\_at*SEC22B*1,24E-042,0202684Down221268_s\_at*SGPP1*0,0331150142,0768883Down223391_at*SGPP1*0,011810352,085591Down206108_s\_at*SRSF6*0,0025593092,4004695Down209754_s\_at*TMPO*0,0101707572,312462Down223949_at*TMPRSS3*0,027546252,1164422Down201291_s\_at*TOP2A*0,0287593452,3533485Down228588_s\_at*UBE2B*4,92E-042,2184792Down235003_at*UHMK1*0,0026757242,2043898Down206133_at*XAF1*0,0171144622,0860553Down222816_s\_at*ZCCHC2*0,0023875332,2362235Down205739_x\_at*ZNF107*0,001477992,0554366Down243495_s\_at*ZNF652*0,0027301982,3722727Down236033_at*ASB12*1,58E-042,0688426Up1552354_at*CBARP*1,66E-042,162268Up201289_at*CYR61*0,0278912432,8001204Up210764_s\_at*CYR61*0,0353308842,2227159Up1565483_at*EGFR*9,60E-054,008361Up1565484_x\_at*EGFR*1,58E-042,8769505Up1564069_at*HOTTIP*1,74E-042,0109012Up1553657_at*LOC101930115///VWA3A*9,50E-052,086649Up1559502_s\_at*LRRC25*1,37E-042,1343188Up230813_at*P3H2*3,33E-042,3854458Up1557680_at*SAMD15*3,33E-042,2336347Up1568249_at*SNHG17///SNORA71B*1,97E-042,6449728Up1558641_at*SPATA24*5,49E-042,0069237Up1569206_at*TCP11L2*8,09E-052,2803137Up1554400_at*TCTE3*1,26E-042,482754Up1557450_s\_at*WHAMMP2*3,17E-042,0680783Up1553718_at*ZNF548*2,81E-042,12732UpTable 6Gene set enrichment analysis of genes differentially expressed in cases (referred to Gene Ontology Biological Process gene sets).Table 6Gene Set Namep-valueFDR q-valueGO LIPID DIGESTION01GO RESPIRATORY SYSTEM PROCESS00,981GO REGULATION OF SYNCYTIUM FORMATION BY PLASMA MEMBRANE FUSION01GO REGULATION OF MYOBLAST FUSION00,737GO RESPONSE TO MAGNESIUM ION00,691GO HYPEROSMOTIC RESPONSE00,893GO MONOCARBOXYLIC ACID TRANSMEMBRANE TRANSPORTER ACTIVITY01GO SYNAPTIC VESICLE LOCALIZATION01GO MITOTIC CELL CYCLE4,26E-101,89E-06GO CELL PROLIFERATION1,56E-092,08E-06GO CELL CYCLE PROCESS1,80E-092,08E-06GO CELL CYCLE1,88E-092,08E-06GO CELL DEATH8,49E-097,53E-06GO RESPONSE TO UV2,04E-081,51E-05GO POSITIVE REGULATION OF DNA METABOLIC PROCESS2,00E-071,27E-04GO NEGATIVE REGULATION OF NITROGEN COMPOUND METABOLIC PROCESS7,52E-074,17E-04GO CHROMOSOME ORGANIZATION9,53E-074,70E-04GO RESPONSE TO RADIATION1,45E-066,41E-04GO MRNA METABOLIC PROCESS1,68E-066,64E-04GO POSITIVE REGULATION OF RESPONSE TO DNA DAMAGE STIMULUS1,80E-066,64E-04GO RESPONSE TO LIGHT STIMULUS2,24E-067,64E-04GO IN UTERO EMBRYONIC DEVELOPMENT4,09E-061,28E-03GO NEGATIVE REGULATION OF GENE EXPRESSION4,55E-061,28E-03GO DNA GEOMETRIC CHANGE4,62E-061,28E-03GO REGULATION OF CELL CYCLE5,01E-061,31E-03GO REGULATION OF DNA METABOLIC PROCESS6,81E-061,68E-03GO POSITIVE REGULATION OF TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER7,87E-061,84E-03GO REGULATION OF CELLULAR AMIDE METABOLIC PROCESS8,56E-061,90E-03GO REGULATION OF RNA SPLICING9,47E-062,00E-03GO DNA DEPENDENT DNA REPLICATION1,03E-052,07E-03GO REGULATION OF ALTERNATIVE MRNA SPLICING VIA SPLICEOSOME1,48E-052,86E-03GO POSITIVE REGULATION OF DNA REPAIR1,91E-053,52E-03GO REGULATION OF MRNA METABOLIC PROCESS2,05E-053,64E-03GO NEGATIVE REGULATION OF CELL CYCLE2,66E-054,39E-03GO POSITIVE REGULATION OF BIOSYNTHETIC PROCESS2,67E-054,39E-03GO MACROMOLECULE CATABOLIC PROCESS3,41E-055,24E-03GO DNA CONFORMATION CHANGE3,50E-055,24E-03GO CELL DIVISION3,73E-055,24E-03GO PLACENTA DEVELOPMENT3,79E-055,24E-03GO NEGATIVE REGULATION OF CELLULAR COMPONENT ORGANIZATION3,80E-055,24E-03GO MITOTIC CELL CYCLE CHECKPOINT3,90E-055,24E-03GO REGULATION OF RESPONSE TO DNA DAMAGE STIMULUS4,60E-056,00E-03GO CELLULAR RESPONSE TO DNA DAMAGE STIMULUS5,24E-056,64E-03GO ORGANELLE FISSION5,65E-056,79E-03GO REGULATION OF CATABOLIC PROCESS5,77E-056,79E-03GO POSITIVE REGULATION OF PEPTIDASE ACTIVITY5,81E-056,79E-03GO NUCLEAR TRANSCRIBED MRNA CATABOLIC PROCESS DEADENYLATION DEPENDENT DECAY6,50E-057,39E-03GO DNA METABOLIC PROCESS7,23E-058,02E-03GO LEUKOCYTE HOMEOSTASIS7,57E-058,19E-03GO REGULATION OF MRNA SPLICING VIA SPLICEOSOME8,35E-058,82E-03GO POSITIVE REGULATION OF CELL CYCLE8,82E-059,10E-03GO POSITIVE REGULATION OF GENE EXPRESSION1,02E-041,02E-02GO EMBRYO DEVELOPMENT ENDING IN BIRTH OR EGG HATCHING1,04E-041,02E-02GO REGULATION OF CELL CYCLE PROCESS1,08E-041,04E-02GO CELL CYCLE DNA REPLICATION1,17E-041,08E-02GO NEGATIVE REGULATION OF CD4 POSITIVE ALPHA BETA T CELL DIFFERENTIATION1,17E-041,08E-02GO REGULATION OF TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER1,29E-041,17E-02GO IMMUNE SYSTEM DEVELOPMENT1,35E-041,20E-02GO REGULATION OF DENDRITE EXTENSION0,0020,948GO POSITIVE REGULATION OF DENDRITE EXTENSION0,0020,812GO RETINOL METABOLIC PROCESS0,0020,727GO METANEPHROS MORPHOGENESIS0,0020,731GO REGULATION OF CILIUM MOVEMENT0,0041GO REGULATION OF OXIDATIVE PHOSPHORYLATION0,0040,886GO TAU PROTEIN BINDING0,0040,731GO E BOX BINDING0,0040,758GO CELLULAR PIGMENT ACCUMULATION0,0040,744GO PIGMENT ACCUMULATION0,0040,682GO MODIFIED AMINO ACID BINDING0,0041GO ISOPRENOID BINDING0,0041

3.3. IFI16 expression is not related to clinical aggressiveness and survival in MCL {#sec3.3}
-----------------------------------------------------------------------------------

Since IFI16 downregulation appeared to be associated with relevant cellular function modifications \[[@bib19], [@bib20], [@bib21], [@bib22], [@bib23], [@bib24], [@bib25], [@bib26], [@bib28]\], we investigated whether its expression was associated with clinical features. *IFI16* gene expression did not significantly differ in indolent (N = 7) vs. classical (N = 15) MCL cases (p = 0.67) ([Fig. 4](#fig4){ref-type="fig"}A). Similarly, *IFI16* gene expression was not associated with overall survival when it was evaluated as either continuous variable (Cox-regression, p = 0.785), or by 50^th^ percentiles (p = 0.5, [Fig. 4](#fig4){ref-type="fig"}B), or by quartile sub-grouping (p = 0.647, [Fig. 4](#fig4){ref-type="fig"}C). This was somehow surprising as MCL prognosis is strictly associated with proliferation \[[@bib48]\], which in turn appeared to be associated with IFI16. However, in CLL the prognostic value of IFI16 reduction was limited to the subgroups of patients presenting with CD38 and/or ZAP70 expression \[[@bib30]\]. Therefore, we cannot exclude that further investigation in MCL will unveil a prognostic value for this molecule.Fig. 4IFI16 gene expression is not related to clinical aggressiveness and survival in MCL patients. In A, IFI16 gene expression in indolent (N = 7) vs classic (N = 15) MCL cases; in B, overall survival based on IFI16 gene expression (50° percentiles, high vs low); in C, overall survival based on IFI16 gene expression (quartiles, Q1 the lowest, Q4 the highest values).Fig. 4

4. Conclusion {#sec4}
=============

In conclusion, we found that IFI16 is significantly downregulated in MCL, being associated with relevant cellular modifications such as proliferation increase and metabolism activation. Nonetheless the possible functional value of IFI16 down-regulation remains to be assessed and further studies need to be performed to determine its real role in MCL. Similarly, a more extensive evaluation of its prognostic value, in perspective homogeneous series should be assessed. In fact, our study was not specifically designed for clinical correlates, the series being not homogenous and the treatment variable. Finally, the specific potential impact of IFI16 as a diagnostic marker might be assessed in diagnostic accuracy study. In fact, though probably not useful for differentiating MCL from CLL (similarly down regulating it), it might be more relevant for other differential diagnoses such as, for example, CCND1- MCL vs. CD5+ DLBCL, in addition to SOX11.
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[^1]: 4 cases regular; 4 cases reduced.
